1stOncology™: Cancer Intelligence Service – Page 12049 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020

On April 26, 2020 Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) reported that the Company will release its 2020 first quarter financial results on Monday, May 11, 2020, before the market opens (Press release, Eagle Pharmaceuticals, APR 29, 2020, View Source [SID1234556786]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date

Monday, May 11, 2020

Time

8:30 a.m. EDT

Toll free (U.S.)

877-876-9173

International

785-424-1667

Webcast (live and replay)

www.eagleus.com, under the "Investor Relations" section

A replay of the conference call will be available for one week after the call’s completion by dialing 800-839-6803 (US) or 402-220-6056 (International) and entering conference call ID EGRXQ120. The webcast will be archived for 30 days at the aforementioned URL.

NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference

On April 29, 2020 NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., reported that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET (Press release, NantKwest, APR 29, 2020, View Source [SID1234556785]).

A live audio webcast of the conference presentation will be available on the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days.

Dr. Soon-Shiong will present a clinical pipeline update with registrational strategies for NantKwest’s off-the-shelf natural killer cell-based therapeutics in combination with ImmunityBio’s N-803 Interleukin 15 (IL-15) ‘superagonist’ cytokine. He will also provide an update on the companies’ COVID-19 therapeutic and vaccine candidates.

McKesson Declares Quarterly Dividend April 29, 2020

On April 29, 2020 The Board of Directors of McKesson Corporation (NYSE:MCK) reported a regular dividend of 41 cents per share of common stock (Press release, McKesson, APR 29, 2020, View Source [SID1234556784]). The dividend will be payable on July 1, 2020, to stockholders of record on June 1, 2020.

Personalis to Participate at Upcoming Investor Conferences

On April 29, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that company management will participate in three upcoming virtual investor conferences (Press release, Personalis, APR 29, 2020, View Source [SID1234556783]).

Present at the Bank of America Securities 2020 Health Care Conference scheduled to be held virtually on Thursday, May 14, 2020 at 1:00 p.m. Eastern Time.
Present at the UBS Virtual Global Healthcare Conference scheduled to be held virtually on Tuesday, May 19, 2020 at 3:50 p.m. Eastern Time.
Participate at the Oppenheimer’s MedTech Summit scheduled to be held virtually on May 27, 2020.

AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program

On April 29, 2020 AVEO Oncology (NASDAQ: AVEO) reported that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, to sorafenib in 3rd and 4th line renal cell carcinoma, will be presented at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 Virtual Scientific Program being held May 29-May 31, 2020 (Press release, AVEO, APR 29, 2020, View Source [SID1234556782]).

Presentation Details

Title: TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)
First Author: Sumanta K. Pal, MD, Associate Clinical Professor, Department of Medical Oncology and Therapeutics Research, and Co-director, Kidney Cancer Program, at City of Hope Comprehensive Cancer Center
Abstract Number: 5062
Poster Session: Genitourinary Cancer – Kidney and Bladder
Date and Time: A copy of the poster will be available on-demand starting Friday, May 29th, 2020, at 8:00 AM ET

About Tivozanib (FOTIVDA)

Tivozanib (FOTIVDA) is an oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) discovered by Kyowa Kirin and approved for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union, the United Kingdom, Norway, New Zealand and Iceland. It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications.1,2 Tivozanib is being studied in the TIVO-3 trial, which is supporting a regulatory submission of tivozanib in the U.S. seeking marketing approval as a treatment for relapsed or refractory RCC. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models3 and has demonstrated synergy in combination with nivolumab (anti PD-1) in a Phase 2 study in RCC4. Tivozanib has been investigated in several tumor types, including renal cell, hepatocellular, colorectal, ovarian and breast cancers.